Literature DB >> 31670608

Laparoscopic Versus Open Liver Resection for Benign Tumors and Lesions: A Case Matched Study with Propensity Score Matching.

Simon Wabitsch1, Anika Kästner1, Philipp K Haber1, Christian Benzing1, Felix Krenzien1, Andreas Andreou1, Can Kamali1, Klaus Lenz2, Johann Pratschke1, Moritz Schmelzle1.   

Abstract

Background and Aim: In recent years, minimally invasive surgical approaches have gained an increasingly important role in hepatobiliary surgery. The aim of this study was to investigate the safety and potential benefits of laparoscopic liver resection (LLR) compared with open liver resection (OLR) for benign liver tumors and lesions. Patients and
Methods: Between January 2009 and December 2017, 182 patients underwent liver resection for benign liver tumors and lesions at our center. After exclusion of 15 patients, the remaining 167 patients were divided into LLR group (n = 54) and OLR group (n = 113) and were compared with regard to perioperative outcomes. To overcome selection bias, a 1:1 propensity score matching (PSM) was performed. In addition, patients undergoing major hepatectomy were divided into major-LLR and major-OLR groups and perioperative outcomes evaluated.
Results: After PSM, 35 patients were included in the OLR group and 35 patients in the LLR group. The LLR group had a significantly shorter median intensive care unit (ICU) stay (LLR: 1 [0-4] days; OLR: 1 [0-3] days; P = .009) and median hospital stay (length of stay [LOS]) (LLR: 7 [4-14] days; OLR: 10 [5-16] days; P < .001). There were no statistically significant differences in postoperative complications graded as Clavien-Dindo ≥III (LLR: 11.4%; OLR: 2.9%; P = .375) in both groups. Postoperative 90-day mortality was 0% in both groups. When comparing major-LLR (n = 8) with major-OLR (n = 59), patients in the major-LLR group had a significantly longer median operation time (major-LLR: 403 [240-501] minutes; major-OLR: 221.5 [111-529] minutes; P < .001), but a significantly shorter median LOS (major-LLR: 7 [5-14] days; major-OLR: 9 [7-129] days; P = .013). The rate of major complications (Dindo Classification ≥III) for major-LLR was 0% and for major-OLR it was 16.9% (P = .207).
Conclusion: Our case-matched study demonstrates shorter ICU and hospital stay using laparoscopic techniques while maintaining high-quality perioperative outcomes. Based on our findings, we suggest preferring the LLR over OLR for benign liver tumors and lesions regardless of the resection extent.

Entities:  

Keywords:  benign liver tumors; laparoscopic liver surgery; liver surgery

Mesh:

Year:  2019        PMID: 31670608     DOI: 10.1089/lap.2019.0427

Source DB:  PubMed          Journal:  J Laparoendosc Adv Surg Tech A        ISSN: 1092-6429            Impact factor:   1.878


  5 in total

Review 1.  Laparoscopic liver resection: indications, limitations, and economic aspects.

Authors:  Moritz Schmelzle; Felix Krenzien; Wenzel Schöning; Johann Pratschke
Journal:  Langenbecks Arch Surg       Date:  2020-07-01       Impact factor: 3.445

2.  Robotic major liver resections: Surgical outcomes compared with open major liver resections.

Authors:  Hye Yeon Yang; Seoung Yoon Rho; Dai Hoon Han; Jin Sub Choi; Gi Hong Choi
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-02-28

3.  Robotic versus open pancreatic surgery: a propensity score-matched cost-effectiveness analysis.

Authors:  Christian Benzing; Lea Timmermann; Thomas Winklmann; Lena Marie Haiden; Karl Herbert Hillebrandt; Axel Winter; Max Magnus Maurer; Matthäus Felsenstein; Felix Krenzien; Moritz Schmelzle; Johann Pratschke; Thomas Malinka
Journal:  Langenbecks Arch Surg       Date:  2022-03-21       Impact factor: 2.895

4.  LAPAROSCOPIC LIVER RESECTION FOR BENIGN TUMORS: THE CURRENT POSITION.

Authors:  Paulo Herman; Gilton Marques Fonseca; Jaime Arthur Pirola Kruger; Vagner Birk Jeismann; Fabricio Ferreira Coelho
Journal:  Arq Bras Cir Dig       Date:  2022-01-31

5.  Operative Time, Age, and Serum Albumin Predict Surgical Morbidity After Laparoscopic Liver Surgery.

Authors:  Daniel Heise; Jan Bednarsch; Andreas Kroh; Sandra Schipper; Roman Eickhoff; Sven Lang; Ulf Neumann; Florian Ulmer
Journal:  Surg Innov       Date:  2021-02-10       Impact factor: 2.058

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.